Patient characteristics on day −5 and on day 30 (N = 50)
| . | Day −5 . | Day 30 . |
|---|---|---|
| DLBCL/HGBCL, n (%) | 41 (82) | — |
| Age, y | 61.5 (18-84) | — |
| Male, n (%) | 36 (72) | — |
| ECOG performance status 3-4, n (%) | 1 (2) | — |
| Ann Arbor stage III-IV, n (%) | 40 (80) | — |
| Extranodal sites > 1, n (%) | 31 (62) | — |
| IPI score 3-5, n (%) | 26 (52) | — |
| Absolute neutrophil count, × 109/L | 2.77 (0-17.36) | 1.43 (0-9.97) |
| Absolute lymphocyte count, ×109/L | 0.61 (0.02-3) | 0.43 (0-2.5) |
| Absolute monocyte count, ×109/L | 0.475 (0-1.11) | 0.41 (0-1.05) |
| Hemoglobin, g/dL | 10.4 (7.2-14.7) | 10.45 (5.7-15.2) |
| Platelet count, ×109/L | 140 (6-390) | 66.5 (1-270) |
| C-reactive protein, mg/L | 29.6 (0.37-175) | 2.57 (0.15-211) |
| Ferritin, mg/L | 661 (33-9694) | 947 (7.14-30 833) |
| Lactate dehydrogenase, U/L | 336.5 (128-5323) | 214 (107-3693) |
| Previous therapies, n | 3 (2-7) | — |
| Bridging therapy use, n (%) | 21 (42) | — |
| Bridging: chemotherapy | 14 (28) | — |
| Radiation therapy | 4 (8) | — |
| Biological therapy | 3 (6) | — |
| None | 29 (58) | — |
| Refractory disease, n (%) | 42 (84) | — |
| Previous autologous SCT, n (%) | 9 (18) | — |
| Previous allogeneic SCT, n (%) | 1 (2) | — |
| SUVmax | 24.9 (3.5-77.7) | 7.75 (2.6-35.1) |
| . | Day −5 . | Day 30 . |
|---|---|---|
| DLBCL/HGBCL, n (%) | 41 (82) | — |
| Age, y | 61.5 (18-84) | — |
| Male, n (%) | 36 (72) | — |
| ECOG performance status 3-4, n (%) | 1 (2) | — |
| Ann Arbor stage III-IV, n (%) | 40 (80) | — |
| Extranodal sites > 1, n (%) | 31 (62) | — |
| IPI score 3-5, n (%) | 26 (52) | — |
| Absolute neutrophil count, × 109/L | 2.77 (0-17.36) | 1.43 (0-9.97) |
| Absolute lymphocyte count, ×109/L | 0.61 (0.02-3) | 0.43 (0-2.5) |
| Absolute monocyte count, ×109/L | 0.475 (0-1.11) | 0.41 (0-1.05) |
| Hemoglobin, g/dL | 10.4 (7.2-14.7) | 10.45 (5.7-15.2) |
| Platelet count, ×109/L | 140 (6-390) | 66.5 (1-270) |
| C-reactive protein, mg/L | 29.6 (0.37-175) | 2.57 (0.15-211) |
| Ferritin, mg/L | 661 (33-9694) | 947 (7.14-30 833) |
| Lactate dehydrogenase, U/L | 336.5 (128-5323) | 214 (107-3693) |
| Previous therapies, n | 3 (2-7) | — |
| Bridging therapy use, n (%) | 21 (42) | — |
| Bridging: chemotherapy | 14 (28) | — |
| Radiation therapy | 4 (8) | — |
| Biological therapy | 3 (6) | — |
| None | 29 (58) | — |
| Refractory disease, n (%) | 42 (84) | — |
| Previous autologous SCT, n (%) | 9 (18) | — |
| Previous allogeneic SCT, n (%) | 1 (2) | — |
| SUVmax | 24.9 (3.5-77.7) | 7.75 (2.6-35.1) |
Unless otherwise noted, data are median (range). Pre-CAR T SUVmax was reported only for patients who had a PET-CT scan performed before lymphodepleting chemotherapy, without interposed bridging therapy.
DLBCL, diffuse LBCL; ECOG, Eastern Cooperative Oncology Group; HGBCL, high-grade B-cell lymphoma; IPI, internal prognostic index; LDH, lactate dehydrogenase; SCT, stem cell transplant.